XNAS
TransCode Therapeutics Inc is a clinical-stage biotechnology company engaged in the development of RNA-based therapeutics and immuno-oncology treatments for cancer. The company's lead candidate, TTX-MC138, targets microRNA-10b and has completed a Phase 1a clinical trial, while it is also advancing additional product candidates, including a cancer vaccine and an oncolytic immunotherapy platform.
| Date | Period | EPS Est. | EPS Act. | Surprise | Revenue | Result | 1D Δ | 1W Δ | 1M Δ |
|---|---|---|---|---|---|---|---|---|---|
| 2026-05-15 | Q1 2026 | — | -21.28 | — | $0 | — | +0.00% | -5.45% | — |
| 2026-04-15 | Q4 2025 | — | -18.10 | — | $0 | — | -3.29% | -3.51% | -25.93% |
| 2025-11-14 | Q3 2025 |
| — |
| -5.82 |
| — |
| $0 |
| — |
| — |
| — |
| — |
| 2024-11-14 | Q3 2024 | -16.17 | -5.28 | +67.35% | $0 | ✅ Beat | -2.92% | +8.60% | -41.71% |
| 2024-08-14 | Q2 2024 | -19.14 | -24.42 | -27.59% | $0 | ❌ Miss | +9.70% | +22.69% | +13.69% |
| 2024-05-15 | Q1 2024 | -16.50 | -21.45 | -30.00% | $0 | ❌ Miss | +9.70% | +78.53% | +48.77% |
| 2024-04-01 | Q4 2023 | -356.40 | -30.69 | +91.39% | $0 | ✅ Beat | -1.43% | -5.35% | -8.99% |
| 2023-11-14 | Q3 2023 | -1438.80 | -2217.60 | -54.13% | $0 | ❌ Miss | -9.34% | -27.32% | -46.66% |
Showing last 8 quarters.